Teladoc faces securities fraud investigation after cutting 2026 revenue forecast and stock plunges 38%.

Teladoc Health announced a lowered revenue forecast for 2026, citing challenges with its BetterHelp platform and cash pay model. Following this, its stock price dropped 38.32% to $6.58 per share. Pomerantz LLP has launched an investigation into whether Teladoc and its executives engaged in securities fraud or other illegal practices. Investors affected by the stock decline may join a class action lawsuit as the case develops.